Tenax Therapeutics Inc news

   Watch this stock
Showing stories 1 - 10 of about 29   

Articles published

TENX 4.01 +0.14 (3.62%)
price chart
Oxygen Biotherapeutics Announces Name Change to Tenax Therapeutics ...
�We are very pleased to unveil this new company name as we continue moving forward as Tenax Therapeutics,� said John Kelley, Chief Executive Officer.
Beleagured Morrisville drug developer changes name, sharpens focus  Triangle Business Journal
Related articles »  
Achillion Pharmaceuticals Inc (ACHN), Tenax Therapeutics Inc (TENX): Peter ...
As a result, RA Capital Management is left holding 8.03 million shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). In another move, the fund's manager, Peter Kolchinsky, has initiated a position in Tenax Therapeutics Inc (NASDAQ:TENX). According ...
Related articles »  
Tenax Therapeutics to Provide Corporate Update and Discuss First Quarter ...
MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (NASDAQ: TENX), formerly Oxygen Biotherapeutics, Inc., today announced that the Company will host a conference call and live audio webcast on Wednesday, September 24, 2014, at 8:30 ...
Related articles »  
Tenax Therapeutics Announces First Patients Enrolled in Phase 3 LEVO-CTS ...
MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (NASDAQ: TENX), formerly Oxygen Biotherapeutics, Inc., a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, ...
Morrisville's Tenax studies experimental drug in cardiac surgery patients  Triangle Business Journal
Related articles »  
Tenax Therapeutics' (TENX) CEO John Kelley on Q1 2015 Results - Earnings ...
Greetings and welcome to the Tenax Therapeutics First Quarter 2015 Earnings call. At this time, all participants are in a listen-only mode.
Tenax Therapeutics Announces First Quarter Fiscal Year 2015 Financial Results  Business Wire (press release)
Related articles »  
Tenax Therapeutics (TENX) Jumps: Stock Moves Up 7.8%
Tenax Therapeutics, Inc. (TENX) was a big mover last session, as its shares rose nearly 8% on the day. The move came on solid volume too with far more shares changing hands than in a normal session.
Related articles »  
Tenax Therapeutics Analyst Brief: Emerging Biopharmaceutical Player Back In ...
NEW YORK, Oct. 31, 2014 /PRNewswire/ -- Analyst Brief by Small Cap Traders. Tenax Therapeutics, Inc. TENX, -2.12% an emerging competitor, is engaged in the business of developing biotechnology products in the nature of blood substitutes with a focus ...
Related articles »  
Oxygen Biotherapeutics, Inc. (OXBT) news: Oxygen Biotherapeutics surges after ...
Oxygen Biotherapeutics' (OXBT) shares soar 30% after the FDA verbally lifts a hold on clinical trials of the company's Oxycyte treatment for traumatic brain injury (TBI). The FDA's decision comes after Oxygen submitted animal study data in September ...
Related articles »  
Oxygen Biotherapeutics, Inc. (OXBT): Oxygen Biotherapeutics acquires ...
"Upon closing of this transaction OXBT will be a company that has a clear path to commercialization with a Phase 3 asset addressing a $600M market," the company notes, adding that levosimendan has Fast Track designation and "an agreed study protocol ...
Oxygen Biotherapeutics To Acquire Certain Assets Of Phyxius Pharma  RTT News
Related articles »  
Oxygen Biotherapeutics Gets Sales Boost From U.S. and Europe
With respect to Oxycyte, the company is continuing work with Oxycyte for traumatic brain injury (TBI). In March 2011, Oxygen Bio was awarded a 2-year, $2.075 million grant from the U.S.